Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Ting-Ting Yang; Ting-Ting Yang; Ting-Ting Yang; Wei-Hao Chen; Wei-Hao Chen; Wei-Hao Chen; Yan-Min Zhao; Yan-Min Zhao; Yan-Min Zhao; Hua-Rui Fu; Hua-Rui Fu; Hua-Rui Fu; He Huang; He Huang; He Huang; Ji-Min Shi; Ji-Min Shi; Ji-Min Shi

doi:10.3389/fonc.2021.672052

Frontiers in Oncology (Apr 2021)

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Ting-Ting Yang,
Ting-Ting Yang,
Ting-Ting Yang,
Wei-Hao Chen,
Wei-Hao Chen,
Wei-Hao Chen,
Yan-Min Zhao,
Yan-Min Zhao,
Yan-Min Zhao,
Hua-Rui Fu,
Hua-Rui Fu,
Hua-Rui Fu,
He Huang,
He Huang,
He Huang,
Ji-Min Shi,
Ji-Min Shi,
Ji-Min Shi

Affiliations

Ting-Ting Yang: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Ting-Ting Yang: Institute of Hematology, Zhejiang University, Hangzhou, China
Ting-Ting Yang: Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
Wei-Hao Chen: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Wei-Hao Chen: Institute of Hematology, Zhejiang University, Hangzhou, China
Wei-Hao Chen: Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
Yan-Min Zhao: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Yan-Min Zhao: Institute of Hematology, Zhejiang University, Hangzhou, China
Yan-Min Zhao: Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
Hua-Rui Fu: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Hua-Rui Fu: Institute of Hematology, Zhejiang University, Hangzhou, China
Hua-Rui Fu: Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
He Huang: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
He Huang: Institute of Hematology, Zhejiang University, Hangzhou, China
He Huang: Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
Ji-Min Shi: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Ji-Min Shi: Institute of Hematology, Zhejiang University, Hangzhou, China
Ji-Min Shi: Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China

DOI: https://doi.org/10.3389/fonc.2021.672052
Journal volume & issue: Vol. 11

Abstract

Read online

Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords